Global Antibody-oligonucleotide Conjugates (AOCs) Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Antibody-oligonucleotide Conjugates (AOCs) market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.
The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.
The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Avidity has successfully concluded positive pre-BLA discussions with the FDA and has adjusted the BLA submission timeline to the first quarter of 2026, aiming to proceed via the U.S. Accelerated Approval pathway. AOC 1044 is expected to become the first commercialized AOC therapeutic. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.
The Antibody-oligonucleotide Conjugates (AOCs) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Antibody-oligonucleotide Conjugates (AOCs) market is split by Type and by Application. For the period 2026-2032, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type,
North America
Europe
Asia-Pacific (China, Japan, South Korea, Rest of Asia)
South America
Middle East & Africa
AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.
The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.
The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Avidity has successfully concluded positive pre-BLA discussions with the FDA and has adjusted the BLA submission timeline to the first quarter of 2026, aiming to proceed via the U.S. Accelerated Approval pathway. AOC 1044 is expected to become the first commercialized AOC therapeutic. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.
The Antibody-oligonucleotide Conjugates (AOCs) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Antibody-oligonucleotide Conjugates (AOCs) market is split by Type and by Application. For the period 2026-2032, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type,
- Site-specific Coupling
- Random Coupling
- Full-length IgG
- Fab
- scFv
- Nanbody/VHH
- Others
- Rare and Genetic Diseases
- Cancer Treatment
- Central Nervous System Disorders
- Avidity Biosciences
- Dyne Therapeutics
- Tallac Therapeutics
- Denali Therapeutics
- Gennao Bio
- ChainGen Bio
North America
Europe
Asia-Pacific (China, Japan, South Korea, Rest of Asia)
South America
Middle East & Africa
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Antibody-oligonucleotide Conjugates (AOCs)
1.2 Classification of Antibody-oligonucleotide Conjugates (AOCs) by Type
1.2.1 Overview: Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type: 2026 Versus 2032
1.2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type in 2032
1.2.3 Site-specific Coupling
1.2.4 Random Coupling
1.3 Classification of Antibody-oligonucleotide Conjugates (AOCs) by Antibody Format
1.3.1 Overview: Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Antibody Format: 2026 Versus 2032
1.3.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Antibody Format in 2032
1.3.3 Full-length IgG
1.3.4 Fab
1.3.5 scFv
1.3.6 Nanbody/VHH
1.3.7 Others
1.4 Global Antibody-oligonucleotide Conjugates (AOCs) Market by Application
1.4.1 Overview: Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application: 2026 Versus 2032
1.4.2 Rare and Genetic Diseases
1.4.3 Cancer Treatment
1.4.4 Central Nervous System Disorders
1.5 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size & Forecast
1.6 Market Drivers, Restraints and Trends
1.6.1 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
1.6.2 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
1.6.3 Antibody-oligonucleotide Conjugates (AOCs) Trends Analysis
2 COMPANY PROFILES
2.1 Avidity Biosciences
2.1.1 Avidity Biosciences Details
2.1.2 Avidity Biosciences Major Business
2.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.1.4 Avidity Biosciences Recent Developments and Future Plans
2.2 Dyne Therapeutics
2.2.1 Dyne Therapeutics Details
2.2.2 Dyne Therapeutics Major Business
2.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.2.4 Dyne Therapeutics Recent Developments and Future Plans
2.3 Tallac Therapeutics
2.3.1 Tallac Therapeutics Details
2.3.2 Tallac Therapeutics Major Business
2.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.3.4 Tallac Therapeutics Recent Developments and Future Plans
2.4 Denali Therapeutics
2.4.1 Denali Therapeutics Details
2.4.2 Denali Therapeutics Major Business
2.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.4.4 Denali Therapeutics Recent Developments and Future Plans
2.5 Gennao Bio
2.5.1 Gennao Bio Details
2.5.2 Gennao Bio Major Business
2.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.5.4 Gennao Bio Recent Developments and Future Plans
2.6 ChainGen Bio
2.6.1 ChainGen Bio Details
2.6.2 ChainGen Bio Major Business
2.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.6.4 ChainGen Bio Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue and Share by Players (2026 & 2032)
3.2 Antibody-oligonucleotide Conjugates (AOCs) Players Head Office, Products and Services Provided
3.3 Antibody-oligonucleotide Conjugates (AOCs) Mergers & Acquisitions
3.4 Antibody-oligonucleotide Conjugates (AOCs) New Entrants and Expansion Plans
4 GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES (AOCS) FORECAST BY REGION
4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2026 VS 2032
4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region, (2026-2032)
4.3 North America
4.3.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in North America
4.3.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in North America
4.3.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
4.4 Europe
4.4.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Europe
4.4.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Europe
4.4.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
4.5 Asia-Pacific
4.5.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
4.5.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
4.5.3 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
4.5.4 China
4.5.5 Japan
4.5.6 South Korea
4.6 South America
4.6.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in South America
4.6.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in South America
4.6.3 South America Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
4.7 Middle East & Africa
4.7.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
4.7.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
4.7.3 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
5 MARKET SIZE SEGMENT BY TYPE
5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Forecast by Type (2026-2032)
5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Type (2026-2032)
6 MARKET SIZE SEGMENT BY APPLICATION
6.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Forecast by Application (2026-2032)
6.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Application (2026-2032)
7 RESEARCH FINDINGS AND CONCLUSION
8 APPENDIX
8.1 Methodology
8.2 Research Process and Data Source
8.3 Disclaimer
1.1 Product Overview and Scope of Antibody-oligonucleotide Conjugates (AOCs)
1.2 Classification of Antibody-oligonucleotide Conjugates (AOCs) by Type
1.2.1 Overview: Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type: 2026 Versus 2032
1.2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type in 2032
1.2.3 Site-specific Coupling
1.2.4 Random Coupling
1.3 Classification of Antibody-oligonucleotide Conjugates (AOCs) by Antibody Format
1.3.1 Overview: Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Antibody Format: 2026 Versus 2032
1.3.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Antibody Format in 2032
1.3.3 Full-length IgG
1.3.4 Fab
1.3.5 scFv
1.3.6 Nanbody/VHH
1.3.7 Others
1.4 Global Antibody-oligonucleotide Conjugates (AOCs) Market by Application
1.4.1 Overview: Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application: 2026 Versus 2032
1.4.2 Rare and Genetic Diseases
1.4.3 Cancer Treatment
1.4.4 Central Nervous System Disorders
1.5 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size & Forecast
1.6 Market Drivers, Restraints and Trends
1.6.1 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
1.6.2 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
1.6.3 Antibody-oligonucleotide Conjugates (AOCs) Trends Analysis
2 COMPANY PROFILES
2.1 Avidity Biosciences
2.1.1 Avidity Biosciences Details
2.1.2 Avidity Biosciences Major Business
2.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.1.4 Avidity Biosciences Recent Developments and Future Plans
2.2 Dyne Therapeutics
2.2.1 Dyne Therapeutics Details
2.2.2 Dyne Therapeutics Major Business
2.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.2.4 Dyne Therapeutics Recent Developments and Future Plans
2.3 Tallac Therapeutics
2.3.1 Tallac Therapeutics Details
2.3.2 Tallac Therapeutics Major Business
2.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.3.4 Tallac Therapeutics Recent Developments and Future Plans
2.4 Denali Therapeutics
2.4.1 Denali Therapeutics Details
2.4.2 Denali Therapeutics Major Business
2.4.3 Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.4.4 Denali Therapeutics Recent Developments and Future Plans
2.5 Gennao Bio
2.5.1 Gennao Bio Details
2.5.2 Gennao Bio Major Business
2.5.3 Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.5.4 Gennao Bio Recent Developments and Future Plans
2.6 ChainGen Bio
2.6.1 ChainGen Bio Details
2.6.2 ChainGen Bio Major Business
2.6.3 ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
2.6.4 ChainGen Bio Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue and Share by Players (2026 & 2032)
3.2 Antibody-oligonucleotide Conjugates (AOCs) Players Head Office, Products and Services Provided
3.3 Antibody-oligonucleotide Conjugates (AOCs) Mergers & Acquisitions
3.4 Antibody-oligonucleotide Conjugates (AOCs) New Entrants and Expansion Plans
4 GLOBAL ANTIBODY-OLIGONUCLEOTIDE CONJUGATES (AOCS) FORECAST BY REGION
4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2026 VS 2032
4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region, (2026-2032)
4.3 North America
4.3.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in North America
4.3.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in North America
4.3.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
4.4 Europe
4.4.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Europe
4.4.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Europe
4.4.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
4.5 Asia-Pacific
4.5.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
4.5.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
4.5.3 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
4.5.4 China
4.5.5 Japan
4.5.6 South Korea
4.6 South America
4.6.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in South America
4.6.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in South America
4.6.3 South America Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
4.7 Middle East & Africa
4.7.1 Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
4.7.2 Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
4.7.3 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size and Prospect (2026-2032)
5 MARKET SIZE SEGMENT BY TYPE
5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Forecast by Type (2026-2032)
5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Type (2026-2032)
6 MARKET SIZE SEGMENT BY APPLICATION
6.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Forecast by Application (2026-2032)
6.2 Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Application (2026-2032)
7 RESEARCH FINDINGS AND CONCLUSION
8 APPENDIX
8.1 Methodology
8.2 Research Process and Data Source
8.3 Disclaimer
LIST OF TABLES
Table 1. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Type, (USD Million) 2026 VS 2032
Table 2. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Antibody Format, (USD Million) 2026 VS 2032
Table 3. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Application, (USD Million), 2026 VS 2032
Table 4. Avidity Biosciences Corporate Information, Head Office, and Major Competitors
Table 5. Avidity Biosciences Major Business
Table 6. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 7. Dyne Therapeutics Corporate Information, Head Office, and Major Competitors
Table 8. Dyne Therapeutics Major Business
Table 9. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 10. Tallac Therapeutics Corporate Information, Head Office, and Major Competitors
Table 11. Tallac Therapeutics Major Business
Table 12. Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 13. Denali Therapeutics Corporate Information, Head Office, and Major Competitors
Table 14. Denali Therapeutics Major Business
Table 15. Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 16. Gennao Bio Corporate Information, Head Office, and Major Competitors
Table 17. Gennao Bio Major Business
Table 18. Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 19. ChainGen Bio Corporate Information, Head Office, and Major Competitors
Table 20. ChainGen Bio Major Business
Table 21. ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 22. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) by Players (2026 & 2032)
Table 23. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Share by Players (2026 & 2032)
Table 24. Antibody-oligonucleotide Conjugates (AOCs) Players Head Office, Products and Services Provided
Table 25. Antibody-oligonucleotide Conjugates (AOCs) Mergers & Acquisitions in the Past Five Years
Table 26. Antibody-oligonucleotide Conjugates (AOCs) New Entrants and Expansion Plans
Table 27. Global Market Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) Comparison by Region (2026 VS 2032)
Table 28. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Region (2026-2032)
Table 29. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in North America
Table 30. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in North America
Table 31. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Europe
Table 32. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Europe
Table 33. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
Table 34. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
Table 35. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in China
Table 36. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Japan
Table 37. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in South Korea
Table 38. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in South America
Table 39. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in South America
Table 40. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
Table 41. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
Table 42. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Forecast by Type (2026-2032)
Table 43. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Forecast by Application (2026-2032)
Table 1. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Type, (USD Million) 2026 VS 2032
Table 2. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Antibody Format, (USD Million) 2026 VS 2032
Table 3. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Application, (USD Million), 2026 VS 2032
Table 4. Avidity Biosciences Corporate Information, Head Office, and Major Competitors
Table 5. Avidity Biosciences Major Business
Table 6. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 7. Dyne Therapeutics Corporate Information, Head Office, and Major Competitors
Table 8. Dyne Therapeutics Major Business
Table 9. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 10. Tallac Therapeutics Corporate Information, Head Office, and Major Competitors
Table 11. Tallac Therapeutics Major Business
Table 12. Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 13. Denali Therapeutics Corporate Information, Head Office, and Major Competitors
Table 14. Denali Therapeutics Major Business
Table 15. Denali Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 16. Gennao Bio Corporate Information, Head Office, and Major Competitors
Table 17. Gennao Bio Major Business
Table 18. Gennao Bio Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 19. ChainGen Bio Corporate Information, Head Office, and Major Competitors
Table 20. ChainGen Bio Major Business
Table 21. ChainGen Bio Antibody-oligonucleotide Conjugates (AOCs) Product and Solutions
Table 22. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) by Players (2026 & 2032)
Table 23. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Share by Players (2026 & 2032)
Table 24. Antibody-oligonucleotide Conjugates (AOCs) Players Head Office, Products and Services Provided
Table 25. Antibody-oligonucleotide Conjugates (AOCs) Mergers & Acquisitions in the Past Five Years
Table 26. Antibody-oligonucleotide Conjugates (AOCs) New Entrants and Expansion Plans
Table 27. Global Market Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) Comparison by Region (2026 VS 2032)
Table 28. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Region (2026-2032)
Table 29. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in North America
Table 30. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in North America
Table 31. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Europe
Table 32. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Europe
Table 33. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
Table 34. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Asia-Pacific
Table 35. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in China
Table 36. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Japan
Table 37. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in South Korea
Table 38. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in South America
Table 39. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in South America
Table 40. Key Companies of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
Table 41. Current Situation and Forecast of Antibody-oligonucleotide Conjugates (AOCs) in Middle East & Africa
Table 42. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Forecast by Type (2026-2032)
Table 43. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Forecast by Application (2026-2032)
LIST OF FIGURES
Figure 1. Antibody-oligonucleotide Conjugates (AOCs) Picture
Figure 2. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type in 2032
Figure 3. Site-specific Coupling
Figure 4. Random Coupling
Figure 5. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Antibody Format in 2032
Figure 6. Full-length IgG
Figure 7. Fab
Figure 8. scFv
Figure 9. Nanbody/VHH
Figure 10. Others
Figure 11. Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application in 2032
Figure 12. Rare and Genetic Diseases Picture
Figure 13. Cancer Treatment Picture
Figure 14. Central Nervous System Disorders Picture
Figure 15. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size, (USD Million): 2026 VS 2032
Figure 16. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue and Forecast (2026-2032) & (USD Million)
Figure 17. Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
Figure 18. Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
Figure 19. Antibody-oligonucleotide Conjugates (AOCs) Market Trends
Figure 20. Avidity Biosciences Recent Developments and Future Plans
Figure 21. Dyne Therapeutics Recent Developments and Future Plans
Figure 22. Tallac Therapeutics Recent Developments and Future Plans
Figure 23. Denali Therapeutics Recent Developments and Future Plans
Figure 24. Gennao Bio Recent Developments and Future Plans
Figure 25. ChainGen Bio Recent Developments and Future Plans
Figure 26. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Region (2026-2032)
Figure 27. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Region in 2032
Figure 28. North America Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 29. Europe Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 30. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 31. South America Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 32. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 33. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Type (2026-2032)
Figure 34. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Application (2026-2032)
Figure 35. Methodology
Figure 36. Research Process and Data Source
Figure 1. Antibody-oligonucleotide Conjugates (AOCs) Picture
Figure 2. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type in 2032
Figure 3. Site-specific Coupling
Figure 4. Random Coupling
Figure 5. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Antibody Format in 2032
Figure 6. Full-length IgG
Figure 7. Fab
Figure 8. scFv
Figure 9. Nanbody/VHH
Figure 10. Others
Figure 11. Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application in 2032
Figure 12. Rare and Genetic Diseases Picture
Figure 13. Cancer Treatment Picture
Figure 14. Central Nervous System Disorders Picture
Figure 15. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size, (USD Million): 2026 VS 2032
Figure 16. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue and Forecast (2026-2032) & (USD Million)
Figure 17. Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
Figure 18. Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
Figure 19. Antibody-oligonucleotide Conjugates (AOCs) Market Trends
Figure 20. Avidity Biosciences Recent Developments and Future Plans
Figure 21. Dyne Therapeutics Recent Developments and Future Plans
Figure 22. Tallac Therapeutics Recent Developments and Future Plans
Figure 23. Denali Therapeutics Recent Developments and Future Plans
Figure 24. Gennao Bio Recent Developments and Future Plans
Figure 25. ChainGen Bio Recent Developments and Future Plans
Figure 26. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Region (2026-2032)
Figure 27. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Region in 2032
Figure 28. North America Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 29. Europe Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 30. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 31. South America Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 32. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Revenue (USD Million) and Growth Rate (2026-2032)
Figure 33. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Type (2026-2032)
Figure 34. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share Forecast by Application (2026-2032)
Figure 35. Methodology
Figure 36. Research Process and Data Source
